Consent in Alzheimer's disease research: Risk/benefit factors

Canadian Journal of Neurological Sciences

Volumn 34, Issue SUPPL. 1, 2007, Pages

  Beattie, B Lynn ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; PLACEBO;

ALZHEIMER DISEASE; CLINICAL COMPETENCE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; HUMAN; IMMUNOTHERAPY; INFORMED CONSENT; MEDICAL DECISION MAKING; MEDICAL ETHICS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; T LYMPHOCYTE ACTIVATION;

EID: 34248546184     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100005527     Document Type: Conference Paper

References (28)

1. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. Medical Research Council of Canada, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada. Public Works and Government Services Canada; 2005.
2. Emanuel EJ, Crouch RA, Arras JD, editors. Ethical and regulatory aspects of clinical research: readings and commentary. Baltimore, Maryland, USA. The Johns Hopkins University Press; 2003.
3. Buckles VD, Powlishta KK, Palmer JL, Coats M, Hosto T, Buckley A, et al. Understanding of informed consent by demented individuals. Neurology. 2003; 61(12):1662-6.
4. Hirschman KB, Xie SX, Feudtner C, Karlawish JH. How does an Alzheimer's disease patient's role in medical decision making change over time? J Geriatr Psychiatry Neurol. 2004; 17(2): 55-60.
5. Kim SY, Appelbaum PS, Jeste DV, Olin JT. Proxy and surrogate consent in geriatric neuropsychiatric research: update and recommendations. Am J Psychiatry. 2004; 161(5):797-806.
6. Pucci E, Belardinelli N, Borsetti G, Rodriguez D, Signorino M. Information and competency for consent to pharmacologic clinical trials in Alzheimer disease: an empirical analysis in patients and family caregivers. Alzheimer Dis Assoc Disord. 2001; 15(3):146-54.
7. Warren JW, Sobal J, Tenney JH, Hoopes JM, Damron D, Levenson S, et al. Informed consent by proxy. An issue in research with elderly patients. N Engl J Med. 1986; 315(18):1124-8.
8. Ouslander JG, Tymchuk AJ, Rahbar B. Health care decisions among elderly long-term care residents and their potential proxies. Arch Intern Med. 1989; 149(6):1367-72.
9. Seckler AB, Meier DE, Mulvihill M, Paris BE. Substituted judgment: how accurate are proxy predictions? Ann Intern Med. 1991; 115(2):92-8.
10. Sachs GA. Advance consent for dementia research. Alzheimer Dis Assoc Disord. 1994; 8(Suppl. 4):S19-27.
11. Muncie HL, Jr., Magaziner J, Hebel JR, Warren JW. Proxies' decisions about clinical research participation for their charges. J Am Geriatr Soc. 1997; 45(8):929-33.
12. Williams BF, French JK, White HD. Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study. Lancet. 2003; 361(9361):918-22.
13. Lewis BS, Yuval R, Halon DA, Flugelman MY. Selection bias introduced by the informed consent process. Lancet. 2003; 361(9373):1990-1.
14. Sugarman J, Cain C, Wallace R, Welsh-Bohmer KA. How proxies make decisions about research for patients with Alzheimer's disease. J Am Geriatr Soc. 2001; 49(8):1110-9.
15. Karlawish JH, Casarett D. Addressing the ethical challenges of clinical trials that involve patients with dementia. J Geriatr Psychiatry Neurol. 2001; 14(4):222-8.
16. Beck C, Shue V. Surrogate decision-making and related issues. Alzheimer Dis Assoc Disord. 2003; 17 Suppl 1:S12-16.
17. Guidance notes for new applications for clinical ethical review by the UBC Clinical Research Ethics Board. Appendix 1. 2006. www.ors.ubc.ca/ethics/ clinical/CREB_GN/CREB_Guidance_Notes.html.
18. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999; 400(6740):173-7.
19. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci. 2002; 3(10):824-8.
20. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003; 38(4):547-54.
21. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003; 61(1):46-54.
22. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004; 14(1):11-20.
23. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markhan H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003; 9(4):448-52.
24. White AR, Hawke SH. Immunotherapy as a therapeutic treatment for neurodegenerative disorders. J Neurochem. 2003; 87(4): 801-8.
25. Robinson SR, Bishop GM, Lee HG, Munch G. Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging. 2004; 25(5):609-15.
26. McGeer PL, McGeer E. Is there a future for vaccination as a treatment for Alzheimer's disease? Neurobiol Aging. 2003; 24(3):391-5.
27. Heppner FL, Gandy S, McLaurin J. Current concepts and future prospects for Alzheimer disease vaccines. Alzheimer Dis Assoc Disord. 2004; 18(1):38-43.
28. Post SG. Full-spectrum proxyu consent for research participation when persons with Alzheimer disease lose decisional capacities: research ethics and the common good. Alzheimer Dis Assoc Disord. 2003; 17 Suppl 1:S3-11.